The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 18 of the 30 sources its claims cite were checked for support.
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Open accessAbstract
Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants: In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days' duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing. Interventions: Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support. Main Outcomes and Measures: The primary outcome was change in central rater-assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment. Results: A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,-12.3 [95% CI, -17.5 to -7.2]; P <.001) and from baseline to day 8 (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001). Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, -2.31 [95% CI, 3.50-1.11]; P < .001) from baseline to day 43. More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin. There were no serious treatment-emergent AEs; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs. Conclusions and Relevance: Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin-when administered with psychological support-may hold promise as a novel intervention for MDD. Trial Registration: ClinicalTrials.gov Identifier: NCT03866174.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
45 Own result · 17 Own method · 8 Partly supported · 5 Own interpretation · 4 No full text of the sources · 3 Supported so far · 3 Couldn’t confirm · 2 No basis given · 1 Sources not found · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Psilocybin shows promise as a treatment for major depressive disorder (MDD).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [6] 6. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12): 1181-1197. doi:10.1177/0269881116675513 sourceExperimental — accuracy not yet measured
The Abstract reports substantial, sustained decreases in depressed mood after psilocybin, and Methods > Study participants says 18 of the 51 patients had an MDD diagnosis, including four also diagnosed with generalized anxiety disorder. But the results concern a mixed group of patients with life-threatening cancer and do not establish the effect specifically for MDD patients or for MDD more generally. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [7] 7. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166. doi:10.1177/ 0269881119897615 source
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Discussion (Primary outcomes; page unavailable) reports sustained reductions in depression symptoms among patients with life-threatening cancer and cites a separate open-label study in treatment-resistant depression. This supports the cautious phrase “shows promise,” but this trial did not test psilocybin as a treatment for MDD specifically; its participants had cancer-related distress and anxiety-related diagnoses (Methods, Study sample and setting; page unavailable). (LLM, conf=0.84)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Nonetheless, placebo response rates in the current study are smaller than are typically observed with daily placebo pills, 34 which may have inflated the placebo-adjusted effect size compared with studies of standard antidepressants in patients with MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Could not verifycites [34] 34. Williams MT, Reed S, Aggarwal R. Culturally informed research design issues in a study of MDMA-assisted psychotherapy for posttraumatic stress disorder. J Psychedelic Stud. 2019;4(1):40-50. doi:10.1556/2054.2019.016 sourceExperimental — accuracy not yet measured
The Introduction contrasts MDMA given 2–3 times with medications often taken daily, but it does not compare placebo response rates. Searches for daily placebo pills, MDD, and placebo-adjusted effect size found no passage addressing the cited claim that placebo responses were smaller than those typically observed with daily pills. (LLM, conf=0.76)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 8% rate of severe adverse events in participants receiving psilocybin was similar to the 10% rate reported in the study by Goodwin et al in participants with TRD treated with a single 25-mg dose of psilocybin.14”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Partly supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 sourceExperimental — accuracy not yet measured
The Safety section reports severe adverse events in 9% of the 25-mg group from day 2 through week 3, but does not report the claimed 10% rate. Table 3 also gives separate rates of 4% on day 1 and 3% after week 3; these interval-specific rates do not establish a 10% overall rate. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the success of allocation blinding was not assessed, and it is likely that the acute psychoactive effects of psilocybin produced some degree of functional unblinding that may have contributed to the observed effect in psilocybin-treated (psilocybin -niacin).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Partly supportedcites [33] 33. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245. doi:10.1186/s12888-018- 1824-6 sourceExperimental — accuracy not yet measured
The Results > Study methodologies section says that finding a placebo that mimics psychedelics’ physiological effects is an important issue for double-blinded trials. That supports a general concern about blinding, but the paper does not say that psilocybin caused functional unblinding in the psilocybin–niacin comparison or that unblinding contributed to its observed effect. No page number is available in our copy. (LLM, conf=0.78)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Nonetheless, placebo response rates in the current study are smaller than are typically observed with daily placebo pills, 34 which may have inflated the placebo-adjusted effect size compared with studies of standard antidepressants in patients with MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Could not verifycites [34] 34. Williams MT, Reed S, Aggarwal R. Culturally informed research design issues in a study of MDMA-assisted psychotherapy for posttraumatic stress disorder. J Psychedelic Stud. 2019;4(1):40-50. doi:10.1556/2054.2019.016 sourceExperimental — accuracy not yet measured
The Introduction describes MDMA-assisted psychotherapy for PTSD and contrasts its dosing schedule with medications taken daily, but it does not compare placebo response rates. Searches of our copy for daily placebo pills and placebo-adjusted effects found no passage addressing the claimed comparison. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and from baseline to day 8 (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001).”
- Also stated in: § Efficacy · plain
“and from baseline to day 8 (key secondary end point) (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 104 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no serious treatment-emergent AEs”
- Also stated in: § Discussion · plain
“No serious TEAEs were reported in the current study”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“More participants receiving psilocybin than niacin had sustained depressive symptom response (20/48 [42%] vs 5/44 [11%]; adjusted absolute difference, 30.3 [95% CI, 13.5-47.1];P = .002;OR, 5.6 [95% CI, 1.9-16.7];P = .002)”
- Also stated in: § Abstract · plain
“More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and a higher rate of severe AEs.”
- Also stated in: § Safety · plain
“Severe related AEs through day 9 were reported by 4 of 50 participants (8%) receiving psilocybin (migraine in 1 participant, headache in 1 participant, illusion in 1 participant [all solicited], and panic attack and paranoia in 1 participant) vs 0 in the niacin group.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, -2.31 [95% CI, 3.50-1.11];P < .001)from baseline to day 43.”
- Also stated in: § Efficacy · plain
“Mean change difference in SDSassessed functional disability score from baseline to day 43 was greater in the psilocybin vs niacin group (-2.31 [95% CI, 3.50-1.11];P < .001)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 104 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy · plain
- It may state two separate claims as one. 21
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent critiques highlight notable limitations in many of these studies, [16][17][18][19] including small sample sizes, assessments by raters likely to be functionally unblinded, an open or waitlist comparator design, and an inadequate assessment of adverse events (AEs).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [16] 16. Hall WD, Humphreys K. Is good science leading the way in the therapeutic use of psychedelic drugs? Psychol Med. 2022;52(14):2849-2851. doi: 10.1017/S0033291722003191 sourceExperimental — accuracy not yet measured
In “Lowering of standards by major medical journals” (page unavailable), the paper describes a psilocybin trial with 30 and 29 patients in its two arms, calls it underpowered, and questions whether participants remained blinded. It does not say that outcome raters were functionally unblinded or that the studies used open or waitlist comparators or inadequately assessed adverse events. The trial it discusses used escitalopram as its comparator. (LLM, conf=0.87)
- Partly supportedcites [17] 17. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10. 1177/02698811221116926 sourceExperimental — accuracy not yet measured
The Discussion > Limitations section (page unavailable) says the included studies were mostly small and that few assessed adverse events systematically. The Psilocybin section identifies open-label studies, and the Limitations section notes difficulty blinding participants. Our copy does not establish that outcome raters were functionally unblinded or that studies used waitlist comparators. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [18] 18. Yaden DB, Potash JB, Griffiths RR. Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry. 2022;79(10):943-944. doi:10.1001/ jamapsychiatry.2022.2546 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Larger recent studies have addressed these issues to various degrees, but report primary end points of short duration, 14,15 leaving open the question of the long-term clinical utility of psilocybin for an often chronic condition such as MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The Discussion says this trial addressed limitations of earlier studies and had a primary end point at 3 weeks, despite 12 weeks of follow-up. The Abstract says larger and longer trials are needed to determine psilocybin’s efficacy and safety for treatment-resistant depression, supporting the claim that its longer-term clinical utility remains open. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent studies suggesting that psilocybin engenders a rapid antidepressant response that far outlasts the presence of the drug in the body.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [6] 6. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12): 1181-1197. doi:10.1177/0269881116675513 sourceExperimental — accuracy not yet measured
The Results (Outcome measures; page unavailable) report a substantial antidepressant response in patients with life-threatening cancer at five weeks, sustained at six months. The Methods (Outcome measures; page unavailable) say the subjective drug effects had subsided by seven hours, supporting that the benefit outlasted the acute effects. But depression was first assessed five weeks after dosing, so this study does not establish how rapidly the antidepressant response began or when the drug left the body. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [7] 7. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166. doi:10.1177/ 0269881119897615 source
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Discussion (Primary outcomes) reports immediate antidepressant effects lasting weeks to months after a single psilocybin dose, given with psychotherapy to patients with life-threatening cancer. The paper does not establish how long the drug remains in the body, so the comparison with its bodily presence is not directly supported. (LLM, conf=0.82)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the success of allocation blinding was not assessed, and it is likely that the acute psychoactive effects of psilocybin produced some degree of functional unblinding that may have contributed to the observed effect in psilocybin-treated (psilocybin -niacin).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Partly supportedcites [33] 33. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245. doi:10.1186/s12888-018- 1824-6 sourceExperimental — accuracy not yet measured
The Results > Study methodologies section (page unavailable) says that a placebo must mimic psychedelic effects for a double-blinded trial, supporting the general concern about blinding. It does not report functional unblinding in a psilocybin–niacin comparison or link it to treatment effects or niacin-group dropout. (LLM, conf=0.82)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one. The quote only partly states this claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Niacin was used as an active placebo that produces an acute physiological response (flushing) thought to aid in blinding.8,22”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
What the sources say
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Methods section (Study design and interventions; page unavailable) identifies niacin as the active control in a double-blind psilocybin trial. Our copy does not state that niacin caused flushing or that this physiological response was intended to aid blinding; the section refers readers to supplementary blinding procedures without describing them. (LLM, conf=0.84)
- Could not verifycites [22] 22. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi:10. 1177/0269881108093587 sourceExperimental — accuracy not yet measured
The Preparation of volunteers section discusses blinding and an active placebo, but identifies that placebo as methylphenidate. Searches for niacin and flushing found no passage in our copy addressing niacin’s use, its physiological response, or whether it aided blinding. (LLM, conf=0.72)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The Efficacy section reports an 18% response rate at week 3 in the 1-mg psilocybin comparator group among participants with treatment-resistant depression. That supports the low-dose comparator figure used in the citing paper's comparison; this source is not offered as evidence for the citing study's own placebo rate or the separate MDD study. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Niacin 100 mg is an inactive placebo with no antidepressant effect.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“No serious TEAEs were reported in the current study; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs compared with niacin, with these severe AEs being known effects of psilocybin.17”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Partly supportedcites [17] 17. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10. 1177/02698811221116926 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Moreover, psychedelics may produce AEs not captured by standard rating scales or may induce unrecognized new psychiatric conditions even as they improve target syndromes.32”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Could not verifycites [32] 32. Jones BDM, Razza LB, Weissman CR, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(9):e2125531. doi:10.1001/jamanetworkopen.2021.25531 sourceExperimental — accuracy not yet measured
The Results (page not provided) list an ayahuasca trial and the depression rating scale it used, but do not discuss psychedelic adverse events or new psychiatric conditions. A search of our copy for those risks and for limitations of standard rating scales found no passage addressing the claim. (LLM, conf=0.76)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The citation supports the comparison to a low-dose psilocybin group in participants with treatment-resistant depression: the Efficacy section reports an 18% response rate at week 3 in the 1-mg group. The suggestion that niacin increased comparator believability and placebo response is the citing authors’ own explanation, not a finding attributed to this paper. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sustained depressive symptom remission rate appeared greater with psilocybin, but the difference was not statistically significant (12/48 [25%] for psilocybin vs 4/44 [9.1%] for niacin; adjusted absolute difference, 15.9 [95% CI, 1.0-30.8];P = .05;OR, 3.4 [95% CI, 1.0-11.5])”
- Also stated in: § Discussion · plain
“The 15.9% difference in sustained remission rates between the groups was not significantly different.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 1529 potential participants who completed prescreening, 347 signed informed consent, 240 were excluded at screening, 3 were excluded prior to randomization, and 104 were randomized, received the study drug, and comprised the ITT population (51 in the psilocybin group and 53 in the niacin group)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of mild and moderate drug-related TEAEs in the same period were higher for psilocybin vs niacin (mild: difference, 35% [95% CI, 17.9%-52.9%];RI, 1.8 [95% CI, 1.1-1.8]);moderate: difference, 18% [95% CI, 5.8%-30.8%];RI, 2.3 [95% CI, 1.0-5.7]).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Visual perceptual effects (assessed following resolution of acute drug effects) were reported by 22/50 (44%) psilocybin participants on the day of dosing and by 3/50 (6%) after the dosing day, all resolved by study conclusion”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plainn = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on C-SSRS or MADRS Item 10 scores and confirmed by clinical assessment, no suicidal or self-injurious behavior occurred during the trial and all instances of suicidal ideation were considered passive.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin treatment was associated with improvements in various exploratory end points, including reductions in global disease severity, self-reported depressive and anxiety symptoms, and improvement in quality of life, while having no effect on emotional blunting”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three serious AEs occurred between enrollment and randomization (nephrolithiasis; incisional hernia, obstructive; and appendicitis; Table 3).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe solicited events were reported by 3 participants receiving psilocybin (2 headaches and 1 visual perceptual effects) and 1 headache was reported in a participant receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In contrast to prior psilocybin trials for depression, 8,14,15 there was not a significant reduction in depressive symptoms or a psilocybin/ placebo difference in depressive symptom status at the day 2 assessment (ie, 1 day after dosing)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was administered centrally by the study's clinical research organization via the Advantage eClinical data system.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“One participant randomized to receive psilocybin received the incorrect treatment, resulting in 50 participants receiving psilocybin and 54 receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was a de facto estimand conducted on the intent-to-treat (ITT) population that included all randomized participants analyzed according to randomized treatment group.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“By 6 weeks, 1 participant in the psilocybin group and 9 in the niacin group had withdrawn or been lost to followup”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin was generally well-tolerated, with most AEs being of mild or moderate severity and generally limited to the acute dosing period.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No procedure for α-level control was applied for exploratory end points, therefore P values reported for these outcomes in eTables 4-8 in Supplement 3 should be considered nominal (ie, not adjusted for multiple comparisons).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Participants, study sponsor, and study site personnel were blinded to treatment group until unblinding following data lock.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, the current study does not allow inferences to be drawn regarding whether the antidepressant effect would have diminished over subsequent weeks or been maintained”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“a sample size of 100 participants resulted in 92% power for the primary day 43 end point and 98% power for the key secondary day 8 end point.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“A minimal clinically important difference (MCID) in change in MADRS score was not prespecified, although depression trial literature supports a placebo-adjusted change in score as low as 2 and as high as 9 and an absolute change from pretreatment of 6 as clinically meaningful and a change of 12 as clinically substantial.25,26”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy Assessments
What the sources say
- Not checked — no full text of the sourcecites [25] 25. Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med. 2022;27(2):69-73. doi:10.1136/ bmjebm-2020-111600 source
- Not checked — no full text of the sourcecites [26] 26. Kobak KA, Williams JB, Jeglic E, Salvucci D, Sharp IR. Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone. Depress Anxiety. 2008;25(11):913-919. doi:10.1002/da.20392 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“eligible participants were randomized in a 1:1 ratio using permuted blocks with random block sizes of 2, 4, and 6, with randomization stratified by site”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To help address this issue, the current study used off-site centralized raters to reduce the potential impact of unblinding on the assessment of outcomes.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sequential significance testing procedure was used to control the overall α level at .05 for primary and secondary end points.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analyses using multiple imputation methods were run for the primary and key secondary outcomes.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Niacin 100 mg is an inactive placebo with no antidepressant effect.
“compared with a 100-mg dose of niacin placebo administered under an identical protocol.”
“the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In some instances, control groups consisted of waiting lists rather than active comparators, 60,73 and therapeutic settings were sometimes not consistently provided. 74,76”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blinding procedures were not consistently robust, 26,32,60,72-76 and comparison with placebo or standard treatments was lacking in many studies. 25,26,31-33,39,57,60,72,73,75-81”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
“difference, 38% [95% CI, 20.6%-41.3%]”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Conclusions
“| At least 1 related AE c | 41 (82) | 24 (44) | 41 (82) | 24 (44) | 38 (20.6 to 54.6) 2 (4) | 1 (2) | 2 (-4.4 to 8.7) | |”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Self-citation
Cited by
Sorted by citations
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 308
Self-citationManagement of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
“…Goodwin et al., 2023a, 2023b; Hollister et al., 1969; Ludwig et al., 1969; Mitchell et al., 2021, 2023; Mithoefer et al., 2019; Pahnke et al., 1970; Raison et al., 2023; Tomsovic and Edwards, 1970), most of them used small sample sizes with an average of 23.46 participants (SD = 13.30, range = 3…”
InfluentialPsilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E. S., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., et al. (2024) · Med · doi:10.1016/j.medj.2024.01.005 · Cited by 134
Acute Adverse Effects of Therapeutic Doses of Psilocybin
Yerubandi, A., Thomas, J. E., Bhuiya, N. M. M. A., Harrington, C. A., Zapata, L. V., & Caballero, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5960 · Cited by 111
Expectancy Effects in Psychedelic Trials
Szigeti, B., & Heifets, B. D. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.02.004 · Cited by 81
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 81
Structural neural plasticity evoked by rapid-acting antidepressant interventions
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. M., & Kwan, A. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00876-0 · Cited by 81
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103149 · Cited by 63
Deep contrastive learning enables genome-wide virtual screening
Jia, Y., Gao, B., Tan, J., Zheng, J., Hong, X., Zhu, W., Tan, H., Xiao, Y., Tan, L., Cai, H., et al. (2026) · Science · doi:10.1126/science.ads9530 · Cited by 66
“Despite their potent hallucinogenic effects, these psychedelics have demonstrated strong and long-lasting antidepressant effects in both rodent models and humans ( 39, 40 ), making 5HT 2A R a crucial target for the development of next-generation antidepressants.”
Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 62
Erritzøe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102799 · Cited by 68
“Phase 1, 17 Phase 2A 5,18 and Phase 2B 19,20 trials have demonstrated that one or two doses of psilocybin, administered with psychological support, can produce almost immediate reductions in depressive symptoms that may persist for months.”
Essentials of Informed Consent to Psychedelic Medicine
Marks, M., Brendel, R. W., Shachar, C., & Cohen, I. G. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.0184 · Cited by 56
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 58
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
“…mimetics (e.g., NMDAR positive allosteric modulator (PAMs), metabotropic glutamate receptor 2/3 antagonists, α -amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptors (AMPAR) PAMS, serotonergic psychedelics) are being assessed for antidepressant ef fi cacy in clinical trials [35, 48 – 50].”
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review
Hughes, M. E., & Garcia‐Romeu, A. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102711 · Cited by 49
“Three studies 45,52,53 did not report ethnoracial demographic data for all study participants; patients without known race or ethnicity (n = 6) were excluded from statistical analyses.”
BackgroundRoméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 53
Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A. W., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.49026 · Cited by 52
Self-citationPsilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 49
Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states
Muir, J., Lin, S., Aarrestad, I. K., Daniels, H. R., Ma, J., Tian, L., Olson, D. E., & Kim, C. K. (2024) · Science · doi:10.1126/science.adl0666 · Cited by 49
Rucker, J., Roberts, C., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., & Wiegand, F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241246857 · Cited by 47
“A growing body of evidence from controlled clinical trials indicates psychedelics may have therapeutic benefits in a variety of psychiatric disorders (Goodwin et al., 2022; Ko et al., 2023; Nutt et al., 2023; Raison et al., 2023).”
BackgroundLSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up
Holze, F., Gasser, P., Müller, F., Strebel, M., & Liechti, M. E. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.99 · Cited by 46
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
Robison, R. J., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Jemison, J., Karas, S. M., Karlin, D. R., Solomon, T. M., et al. (2025) · JAMA · doi:10.1001/jama.2025.13481 · Cited by 44
Self-citationRichardson, E., Patterson, R., Meltzer-Brody, S. E., McClure, R. W., & Tow, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050423-095712 · Cited by 39
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
Aaronson, S., van der Vaart, A. D., Miller, T. M., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., & Sackeim, H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231063 · Cited by 34
Stimulant and hallucinogenic novel psychoactive substances; an update
Schifano, F., Vento, A. E., Scherbaum, N., & Guirguis, A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279192 · Cited by 39
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)
Zeifman, R. J., Spriggs, M. J., Kettner, H., Lyons, T., Rosas, F. E., Mediano, P. A. M., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Scientific Reports · doi:10.1038/s41598-023-28111-3 · Cited by 62
Psychedelic Therapy—A New Paradigm of Care for Mental Health
Yehuda, R., & Lehrner, A. L. (2023) · JAMA · doi:10.1001/jama.2023.12900 · Cited by 35
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J. K. E., Bessa, B. S., d’Orsi, D., Schoevers, R. A., & Oliveira-Maia, A. J. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00333-x · Cited by 35
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2025.116359 · Cited by 38
Self-citationLuquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., & Sergent, F. (2025) · Addiction · doi:10.1111/add.70152 · Cited by 39
Sinha, J. K., Trisal, A., Ghosh, S., Gupta, S., Singh, D. K. K., Han, S. S., Mahapatra, M., Abomughaid, M. M., Abomughayedh, A. M., Almutary, A. G., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102211 · Cited by 31
A Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 39
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 36
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 35
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Meling, D., Ehrenkranz, R. C., Nayak, S. M., Aicher, H., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024) · Psychoactives · doi:10.3390/psychoactives3020014 · Cited by 35
Self-citationDuque, M., Chen, A., Hsu, E. T., Narayan, S., Rymbek, A., Begum, S., Saher, G., Cohen, A. E., Olson, D. E., Li, Y., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.11.011 · Cited by 31
Ellis, S., Bostian, C. M., Feng, W., Fischer, E. G., Schwartz, G., Eisen, K., Lean, M., Conlan, E., Ostacher, M. J., Aaronson, S. T., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.133 · Cited by 34
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 33
Kirlić, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., Gaillard, A., Goodwin, G. M., & Koelpin, D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230884 · Cited by 35
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 35
Self-citationMüller, F., Zaczek, H., Becker, A., Ley, L., Borgwardt, S., de Jesus, J. S., Loh, N., Kohut, J., Auernig, M., Boehlke, C. S., et al. (2025) · Med · doi:10.1016/j.medj.2025.100725 · Cited by 32
Bhatt, K. V., & Weissman, C. R. (2024) · npj Mental Health Research · doi:10.1038/s44184-023-00053-8 · Cited by 30
Safety pharmacology of acute psilocybin administration in healthy participants
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104060 · Cited by 30
Avram, M., Fortea, L., Wollner, L., Coenen, R., Korda, A. I., Rogg, H. V., Holze, F., Vizeli, P., Ley, L., Raduà, J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02734-y · Cited by 32
“Such investigations hold signi fi cant clinical relevance, especially considering the ongoing exploration of distinct psychedelics for various psychiatric disorders, such as LSD for anxiety disorders [3] and psilocybin for depression [56].”
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression
Hieronymus, F., López, E., Sjögren, H. W., & Lundberg, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.24119 · Cited by 32
Klaiber, A., Schmid, Y., Becker, A., Straumann, I., Erne, L., Jelušić, A., Thomann, J., Luethi, D., & Liechti, M. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03116-2 · Cited by 29
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 34
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Kishon, R., Modlin, N. L., Cycowicz, Y. M., Mourtada, H., Wilson, T., Williamson, V., Cleare, A. J., & Rucker, J. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00068-9 · Cited by 29
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 27
Hsu, T., Tsai, C., Kao, Y., Thompson, T., Carvalho, A. F., Yang, F., Tseng, P., Hsu, C.-W., Yu, C., Tu, Y., et al. (2024) · BMJ · doi:10.1136/bmj-2023-078607 · Cited by 28
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0132 · Cited by 39
Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A. M., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., et al. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2258367 · Cited by 29
“Phase II trials with psilocybin have demonstrated both adequate safety and efficacy outcomes, particularly for major depressive disorder (MDD) and TRD (Goodwin et al. 2022; Raison et al. 2023; Rosenblat et al. 2022).”
BackgroundSelf-citationProtocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 32
Addressing blinding in classic psychedelic studies with innovative active placebos
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D’Souza, D. C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf023 · Cited by 28
“5 In another randomized, placebo-controlled trial, a pulse of low-dose (10 mg/70 kg) psilocybin administered 3 times 5 days apart was followed by a significant reduction in cluster attack frequency in patients with cluster headache.”
Hammo, A., Wisser, S., & Cichon, J. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02068-0 · Cited by 25
Padawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 30
A multi-institutional investigation of psilocybin’s effects on mouse behavior
Lu, O., White, K., Raymond, K. B., Liu, C. J., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A. J., Shindy, L., Li, A., et al. (2026) · Nature Neuroscience · doi:10.1101/2025.04.08.647810 · Cited by 28
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 27
“…depressive disorder (Carhart-Harris, Bolstridge, et al., 2016; Carhart-Harris et al., 2018, 2021; Goodwin et al., 2022; Palhano-Fontes et al., 2019; Raison et al., 2023; Reiff et al., 2020; Rotz et al., 2023; Sanches et al., 2016), anxiety with and without a life-threatening illness (Gasser et…”
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Li, L., Mo, Y., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1416420 · Cited by 28
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230751 · Cited by 27
Wang, E. Y., Mathai, D. S., Gukasyan, N., Nayak, S. M., & Garcia‐Romeu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-78736-1 · Cited by 29
Self-citationAdverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim, B., Sahin, S. S., Gee, A., Jauhar, S., Rucker, J., Salgado‐Pineda, P., Pomarol‐Clotet, E., & McKenna, P. J. (2024) · Psychological Medicine · doi:10.1017/s0033291724002496 · Cited by 28
“Four recent trials (Carhart-Harris et al., 2021; Goodwin et al., 2022; Raison et al., 2023; von Rotz et al., 2023) (one of them large, N = 233; Goodwin et al., 2022) have found evidence for psilocybin ’ s effectiveness in major depressive disorder, leading to the FDA designating it a ‘ breakthrough…”
Psilocybin increases emotional empathy in patients with major depression
Jungwirth, J., von Rotz, R., Dziobek, I., Vollenweider, F. X., & Preller, K. H. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02875-0 · Cited by 27
Nutt, D., Hunt, P., Schlag, A. K., & Fitzgerald, P. B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17398 · Cited by 23
“Another company, Usona, has also achieved very good results in Phase 2 and are also moving to Phase 3 (Raison et al., 2023).”
Pellegrini, L., Fineberg, N. A., O'Connor, S., de Souza, A. M. F. L. P., Godfrey, K., Reed, S., Peill, J. M., Healy, M., Rohani-Shukla, C., Lee, H., et al. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152619 · Cited by 27
Madsen, C. A., Navarro, M. L., Elfving, B., Kessing, L. V., Ċastrén, E., Mikkelsen, J. D., & Knudsen, G. M. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.06.008 · Cited by 26
Shinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03187-1 · Cited by 28
“We encourage future research to develop tools for modelling these relationships in order to improve our scienti fi c understanding of psychedelics.”
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee, T. G., Davoudian, P. A., Sanacora, G., & Wilkinson, S. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103818 · Cited by 23
Self-citationŚwieczkowski, D., Kwaśny, A., Pruc, M., Gaca, Z., Szarpak, P. L., & Cubała, W. J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116337 · Cited by 21
Otto, M. E., van der Heijden, K. V., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., Jacobs, G. E., & van Hasselt, J. G. C. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01454-4 · Cited by 24
Aboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 24
Gong, P., Wang, J., Long, H., Yang, W., Chen, X., Li, N., Chen, F., Zhang, J., & Guo, Y. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70080 · Cited by 21
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Jiang, Q., Shao, L.-X., Yao, S., Savalia, N. K., Gilbert, A. D., Davoudian, P. A., Nothnagel, J. D., Tian, G., Hung, J. T. S., Lai, H. M., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.009 · Cited by 27
Haniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 21
“In various clinical trial designs, psilocybin-assisted psychotherapy has demonstrated rapid amelioration of depressive symptoms, in some patients with MDD and treatment-resistant depression (TRD) (Davis et al., 2021; Goodwin et al., 2023; Raison et al., 2023; von Rotz et al., 2022).”
Havenith, M. N., Leidenberger, M., Brasanac, J., Corvacho, M., Figueiredo, I., Schwarz, L., Uthaug, M. V., Rakusa, S., Bernardic, M., Vasquez-Mock, L., et al. (2025) · Communications Psychology · doi:10.1038/s44271-025-00247-0 · Cited by 30
Nadeem, Z., Parker, S., McGovern, H. T., & Oestreich, L. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241261779 · Cited by 23
“Recent randomized controlled trials of psilocybin have demonstrated rapid and sustained relief from symptoms in individuals with treatment-resistant major depressive disorder (MDD) (Andersen et al., 2021; Goodwin, 2023; Haikazian et al., 2023; Muttoni et al., 2019; Raison et al., 2023).”
BackgroundHumphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 26
The safety of psilocybin-assisted psychotherapy: A systematic review
de Freitas, R. R., Gotsis, E. S., Gallo, A. T., Fitzgibbon, B. M., Bailey, N. W., & Fitzgerald, P. B. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241289024 · Cited by 29
“Peck et al. (2023) observed increased SI at week 3, while Raison et al. (2023) noted increased SI at week 6.”
Aday, J. S., McAfee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C. L., Scott, K., Horowitz, D., Geller, J. A., Harte, S. E., et al. (2025) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1527783 · Cited by 22
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 19
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 20
“Niacin, which induces facial flushing, or a very low dose of the psychedelic has been utilized as a placebo, but a careful evaluation of unblinding and expectation effects has not been performed [158].”
Self-citationRoss, M., Iyer, R., Williams, M. L., Boughey, M., O’Callaghan, C. C., Hiscock, R. J., & Dwyer, J. L. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.08.001 · Cited by 20
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
“Notable adverse reactions in recent large trials of psilocybin have included psychological discomfort (~30%), physical discomfort and anxiety during the session 6,7,11 .”
Williams, Z. J., Barnett, H., & Szigeti, B. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4809 · Cited by 24
Solaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 22
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
“…therapy (PAT) with psilocybin and lysergic acid diethylamide (LSD) has demonstrated efficacy in the treat-ment of depression, anxiety, and some other neuropsychiatric disorders (Gasser et al., 2014; Goodwin et al., 2022; Holze et al., 2023b; Raison et al., 2023; von Rotz et al., 2023).”
BackgroundMenon, V., Ramamurthy, P., Venu, S., & Andrade, C. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13778 · Cited by 21
Jensen, M. E., Stenbæk, D. S., Messell, C., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319457 · Cited by 22
“However, several clinical studies on depression have reported positive outcomes with just one dosing session (Griffiths et al., 2016; Goodwin et al., 2022; Ross et al., 2016; Raison et al., 2023; von Rotz et al.,”
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms
Simonsson, O., Goldberg, S. B., Osika, W., Stenfors, C. U. D., Chaturvedi, S., Swords, C. M., Narayanan, J., & Hendricks, P. S. (2025) · Psychological Medicine · doi:10.1017/s0033291725000716 · Cited by 19
“…is associated with reductions in depressive symptoms in patients with major depressive disorder or treatment-resistant depression (Goodwin et al., 2022; Raison et al., 2023) and reductions in anxiety symptoms in patients with life-threatening cancer (Griffiths et al., 2016; Ross et al., 2016).”
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 21
Højlund, M., Kafalı, H. Y., Kırmızı, B., Fusar‐Poli, P., Correll, C. U., Cortese, S., Sabé, M., Fiedorowicz, J. G., Saraf, G., Zein, J., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.09.011 · Cited by 23
Exploring potential genes and mechanisms linking erectile dysfunction and depression
Yuan, P., Chen, Y., Sun, T., Cui, L., Wei, Y., Li, T., & Meng, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1221043 · Cited by 20
“The transcriptomic data associated with ED and depression were collected from the Gene Expression Omnibus (GEO) database (https:// www.ncbi.nlm.nih.gov/geo/) based on the diagnostic criteria of the diseases in December 2022 (1, 16).”
MethodMolecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 25
“A single dose of psilocybin was associated with a reduction in depressive symptoms without serious adverse events in a randomized clinical study of Raison et al. [154].”
BackgroundCampanale, A., Inserra, A., & Comai, S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111058 · Cited by 19
“…2022; Goodwin et al., 2023a; Griffiths et al., 2016; Gukasyan et al., 2022; Holze et al., 2023; Os ´ orio et al., 2015; Palhano-Fontes et al., 2019; Raison et al., 2023; Ross et al., 2016) and potentially for the negative symptoms of SCZ (Mahmood et al., 2022; Wolf et al., 2023) and BD (Bosch et…”
BackgroundPharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 25
“There has been renewed interest in the potential therapeutic applications of psychedelics such as psilocybin and LSD, especially for depressive, anxiety, and substance use disorders [2 – 8].”
BackgroundPsychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 18
“…conditions, including major depressive disorder (Carhart-Harris et al., 2016, 2021; Davis et al., 2021; D’Souza et al., 2022; Goodwin et al., 2023; Raison et al., 2023), end-of-life anxiety and depression (Griffiths et al., 2016; Grob et al., 2011; Muttoni et al., 2019; Ross et al., 2016), and…”
Self-citationSet and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 18
“…references to more complete manuals containing key data information not in the article nor in the protocol, such as the Yale manual (Guss et al., 2020; Sloshower et al., 2023) although sometimes these were not publicly available, such as the Usona Facilitator Training Manual (Raison et al., 2023).”
Influential
Metadata
- Authors
- Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., Nicholas, C. R., Hutson, P. R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M. C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Johnson, M. W., Ross, S., & Griffiths, R. R.
- Affiliations
- Usona Institute (US)
- Yale University (US)
- San Francisco VA Medical Center (US)
- Pacific Neuroscience Institute, Santa Monica, California
- Emory University (US)
- University of Wisconsin–Madison (US)
- Center for Psychedelic Research, Segal Trials, Lauderhill, Florida
- Hassman Research Institute (US)
- Flourish Research, Chicago, Illinois
- University of Utah (US)
- Johns Hopkins University (US)
- NYU Langone Health (US)
- University of California, San Francisco (US)
- Usona Institute, Fitchburg, Wisconsin
- Emmes (United States) (US)
- Corresponding author
- Raison, Charles L.
- ORCID
- Raison, Charles L.
- Sanacora, Gerard
- Woolley, Joshua
- Heinzerling, Keith
- Dunlop, Boadie W.
- Brown, Randall T.
- Trivedi, Rupal P.
- Robison, Reid
- Gukasyan, Natalie
- Nayak, Sandeep M.
- O’Donnell, Kelley C.
- Kelmendi, Benjamin
- Sloshower, Jordan
- Penn, Andrew D.
- Bradley, Ellen
- Kelly, Daniel F.
- Mletzko, Tanja
- Nicholas, Christopher R.
- Hutson, Paul R.
- Brown, Carrie
- Johnson, Matthew W.
- Ross, Stephen
- Griffiths, Roland R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-09-05
- Volume
- 330
- Issue
- 9
- Pages
- 843
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC10472268
- OpenAlex
- W4386305655
- Cited by
- 545
- References
- 35
- Citations by year
- 2026: 165 · 2025: 212 · 2024: 152 · 2023: 16
- FWCI
- 158.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Center for Advancing Translational Sciences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- psilocybin, major depressive disorder, antidepressant effects, psychological support, depression remission, sustained response, adverse events, antidepressant safety, psychedelic therapy, Sheehan Disability Scale, Montgomery-Asberg Depression Rating Scale, treatment durability
- MeSH terms
- Adult, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Mental Health, Niacin, Psilocybin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
